High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
CGHS would give robust coverage to pensioners and with new innovations and practices
This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats
The move will add new global talent to Cytel’s Strategic Consulting group
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
Cumulatively, almost 75% of the health centres in the country have been electrified with a cumulative solar capacity of 3.5 MW
Subscribe To Our Newsletter & Stay Updated
